Elekta taps Brainlab as US stereotactic neurosurgery distro partner

Elekta (STO:EKTA B) said today it inked an exclusive deal with Brainlab to make it the authorized distributor of Elekta’s stereotactic neurosurgery solutions. Through the deal, Brainlab will be the authorized distributor of Elekta’s Leksell Vantage stereotactic system which won CE Mark approval in the European Union this year. The system also has FDA 510(k) clearance and is commercially available in the US. Stereotactic neurosurgery is a minimally invasive approach to brain surgery designed to treat specific regions of the brain and spare surrounding healthy tissue, and is often used to implant deep brain stimulation leads or to perform lesioning of small brain targets for treating functional disorders. “Early adopters of the Vantage system are experiencing clinical and patient benefits from its multiple design innovations. These include stereotactic magnetic resonance imaging with fewer restrictions, easier target coordinate setting during surgery as well as improved anesthetic capabilities,” Elekta neuro portfolio VP Jesper Söderqvist said in a prepared statement. “We strive to make medical technology more impactful and accessible to physicians and their patients. By partnering with Elekta, we are increasing our reach and providing clinicians with advanced and innovative technology on the stereotactic neurosurgery market,” Brainlab functional & stereotactic neurosurgery VP Paolo Jelmoni said in a prepared release. The deal expands o...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Neurological Brainlab Elekta Source Type: news